sn 38 has been researched along with arc111 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Chan, YW; Chang, CL; Chang, LH; Chao, YT; Chen, SF; Chen, YC; Chen, YF; Chou, SY; Chuang, SH; Gao, YS; Hsu, PC; Hsueh, WY; Huang, GR; Huang, HY; Huang, JJ; Huang, MS; Huang, PH; Huang, SY; Huang, YC; Jian, BH; Kao, YF; Lai, CH; Lee, YE; Lin, HS; Lin, JC; Lin, SF; Lin, YH; Liu, HH; Lo, TH; Lu, YY; Teng, LW; Wang, SY; Wei, WY; Yang, SC; Yuan, TT | 1 |
2 other study(ies) available for sn 38 and arc111
| Article | Year |
|---|---|
12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Phenanthridines; Topoisomerase I Inhibitors | 2009 |
Copper(I)-Catalyzed Nitrile-Addition/
Topics: Animals; Antineoplastic Agents; Catalysis; Copper; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Nitriles; Quinolones; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2021 |